
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is poised for strong growth with their recent acquisition of Naveris and raised guidance for 2026. Their leadership in HPV-related cancer MRD testing provides a strong foundation, and their expansion into other organ types and the digital/IT space offer potential for even more growth. With the potential market for the newly developed AlloHeme assay and their focus on increasing transplant volumes, CareDx has a promising future.
Bears say
CareDx is heavily dependent on its testing services for revenue and has significant ongoing expenses for investments in Epic and RCM initiatives. Its recent sale of its lab products business may be a wise move in terms of fortifying its balance sheet and streamlining operations, but it may also result in a reduction in GMs and require further acquisitions to continue expanding its precision lab testing portfolio. While CDNA has raised its 2026 guidance, there are still potential challenges ahead, including a final LCD decision from Palmetto GBA and competition in the diagnostic testing market.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares